- Home
- TLRY vs TBPH Comparison
TLRY vs TBPH Comparison
Compare TLRY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- TBPH
- Stock Information
- Founded
- TLRY N/A
- TBPH 2013
- Country
- TLRY Canada
- TBPH United States
- Employees
- TLRY N/A
- TBPH N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- TBPH Health Care
- Exchange
- TLRY Nasdaq
- TBPH Nasdaq
- Market Cap
- TLRY 624.7M
- TBPH 699.0M
- IPO Year
- TLRY 2018
- TBPH N/A
- Fundamental
- Price
- TLRY $1.12
- TBPH $14.00
- Analyst Decision
- TLRY Buy
- TBPH Strong Buy
- Analyst Count
- TLRY 4
- TBPH 3
- Target Price
- TLRY $1.58
- TBPH $21.33
- AVG Volume (30 Days)
- TLRY 68.6M
- TBPH 584.2K
- Earning Date
- TLRY 10-09-2025
- TBPH 11-11-2025
- Dividend Yield
- TLRY N/A
- TBPH N/A
- EPS Growth
- TLRY N/A
- TBPH N/A
- EPS
- TLRY N/A
- TBPH 0.26
- Revenue
- TLRY $821,309,000.00
- TBPH $77,205,000.00
- Revenue This Year
- TLRY $7.44
- TBPH $78.36
- Revenue Next Year
- TLRY $4.66
- TBPH N/A
- P/E Ratio
- TLRY N/A
- TBPH $52.86
- Revenue Growth
- TLRY 4.10
- TBPH 24.49
- 52 Week Low
- TLRY $0.35
- TBPH $7.88
- 52 Week High
- TLRY $1.88
- TBPH $14.55
- Technical
- Relative Strength Index (RSI)
- TLRY 52.38
- TBPH 67.87
- Support Level
- TLRY $1.03
- TBPH $13.47
- Resistance Level
- TLRY $1.22
- TBPH $14.36
- Average True Range (ATR)
- TLRY 0.11
- TBPH 0.42
- MACD
- TLRY -0.04
- TBPH -0.09
- Stochastic Oscillator
- TLRY 18.10
- TBPH 49.08
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).